Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of KT-621 Oral Formulations in Healthy Adults
NCT07823205Phase 1Recruiting
- Sponsor
- Kymera Therapeutics
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of KT-621 (2 arms), sponsored by Kymera Therapeutics. Primary endpoints: Maximum Plasma Concentration of KT-621, Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
KT-621
Beyond the preview
Go deeper on NCT07823205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823205.